Boehringer Ingelheim (Norway)

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 11.6K citations · Full text

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Christoph Wanner, Silvio E. Inzucchi, John M. Lachin et al. · New England Journal of Medicine · 2016 · 3.5K citations · Full text

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk

Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen et al. · JAMA · 2018 · 1K citations · Full text

Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism

Sam Schulman, Clive Kearon, Ajay K. Kakkar et al. · New England Journal of Medicine · 2013 · 977 citations · Full text

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

Silvio E. Inzucchi, Bernard Zinman, David Fitchett et al. · Diabetes Care · 2017 · 721 citations